We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    Tricvalve | Tricuspid Regurgitation

TRICUS STUDY - Safety and Efficacy of the TricValve® Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03723239
Recruitment Status : Completed
First Posted : October 29, 2018
Last Update Posted : April 20, 2022
Information provided by (Responsible Party):
P+F Products + Features GmbH

Brief Summary:
The TricValve® Transcatheter Bicaval Valves System is indicated for relief of tricuspid insufficiency in patients with symptomatic heart disease who are judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy.

Condition or disease Intervention/treatment Phase
Severe Tricuspid Regurgitation Device: TricValve® System Not Applicable

Detailed Description:

TricValve® Transcatheter Bicaval Valves is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. It is especially intended for use for patients at extreme risk or who are inoperable for open surgical therapy.

Pre-Clinical and Clinical preliminary studies have shown an acceptable safety and performance profile of the TricValve® Transcatheter Bicaval Valves System. Given that the medical device is a potential long-term treatment for patients with tricuspid insufficiency, clinical data for long-term treatment periods is necessary. Thus, the current study is designed to investigate the safety and performance for at least 30 days and up to 6 months.

The study has been approved by the Kaunas Regional Biomedical Research Ethics Committee.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TRICUS STUDY - Safety and Efficacy of the TricValve® Transcatheter Bicaval Valves System in the Superior and Inferior Vena Cava in Patients With Severe Tricuspid Regurgitation.
Actual Study Start Date : September 12, 2018
Actual Primary Completion Date : September 4, 2020
Actual Study Completion Date : November 15, 2021

Arm Intervention/treatment
Experimental: TricValve® System Single-Arm
Minimally invasive catheter-supported, bicaval tricuspid valve (self-expanding) replacement
Device: TricValve® System
The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.

Primary Outcome Measures :
  1. Percentage of participants with major adverse events [ Time Frame: 30 days ]
    The percentage of participants with major adverse events (death, myocardial infarction, cardiac tamponade, cardiac surgery for failed TricValve® implantation, stroke. Major bleeding according to Valve Academic Research Consortium (VARC) criteria)

  2. Change of New York Heart Association (NYHA) functional class [ Time Frame: 6 months ]
    Change of New York Heart Association (NYHA) functional class from III or IV to a lower one

Secondary Outcome Measures :
  1. Successful implantation [ Time Frame: Up to Discharge (≤ 10 days post index procedure) ]
    The percentage of surviving participants with successful access, delivery and retrieval of the device delivery system, and deployment and correct positioning of the intended device(s), and no need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure.

  2. Unrestricted movement of cusps [ Time Frame: Up to 30 days, up to 6 months ]
    The percentage of medical devices with unrestricted movement of cusps after implantation as assessed with echocardiography (nominal)

  3. Cusp insufficiency [ Time Frame: Up to 30 days, up to 6 months ]
    The change of the degree of cusp insufficiency as assessed with echocardiography (ordinal) from a higher to a lower value

  4. Device success [ Time Frame: Up to 30 days, up to 6 months ]
    Device success as measured by number of patients who are alive with intended device in place with no additional surgical or interventional procedures related to the TricValve®.

  5. NYHA functional class [ Time Frame: Up to 30 days ]
    Number of Patients with improvement of NYHA functional class

  6. 6 Minute Walk Test [ Time Frame: Up to 30 days, up to 6 months ]
    Improvement in distance (m) in the 6 Minute Walk Test

  7. Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Up to 30 days, up to 6 months ]
    Number of Patients with improvement in quality of life as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Range of 0-100, in which higher scores reflect better health status.)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subject must be 18 years of age or older
  2. The subject must be a patient with severe symptomatic tricuspid regurgitation demonstrated by echocardiography with significant backflow in the lower (IVC) and/or upper (SVC) vena cava and with a v-wave ≥ 25 mmHg as demonstrated by right heart catheterization (measured in the IVC and/or SVC 2-4 cm above/ below right atrium (RA) inflow) within 8 weeks prior to the implantation
  3. Suitable for TricValve® Transcatheter Bicaval Valves System implantation according to anatomic criteria by computed tomography
  4. The subjects must have severe, tricuspid regurgitation leading to New York Heart Association (NYHA) class III or IV
  5. The subject has left ventricular ejection fraction (LVEF) ≥ 40%
  6. Distance covert in 6-minute walk test (6MWT) ≥ 60m
  7. The patient shall be screened by a "Heart Team" - including an interventional cardiologist, cardiothoracic surgeon, and agreed as a candidate for the TricValve® Transcatheter Bicaval Valves System implantation
  8. Patient/authorized legal guardian understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent Patient/patient's authorized legal guardian is geographically stable (or willing to return for required study follow-up) and understands and is willing to fulfil all of the expected requirements of the clinical protocol

Exclusion Criteria:

  1. Known significant intracardiac shunt (e.g. ventricular septal defect) or congenital structural heart disease based on heart teams decision
  2. Requirement for other elective cardiac procedures e.g. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) up to 90 days after the procedure or 30 days before the procedure
  3. Right ventricular failure (TAPSE ≤13mmHg)
  4. Systolic pulmonary arterial pressure > 65 mmHg as assessed by Doppler echocardiography
  5. Presence of any known life threatening (noncardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year
  6. Cerebro-vascular event within the past 3 months
  7. History of mitral/tricuspid endocarditis within the last 12 months
  8. Patient has untreated significant left sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis)
  9. Documented primary coagulopathy or platelet disorder, including thrombocytopenia (absolute platelet count <90k)
  10. Documented evidence of significant renal dysfunction (serum creatinine > 3.0mg/dl) or on any form of dialysis at time of screening within the last 4 weeks
  11. Contraindication or known allergy to device's components, anti-coagulation therapy with vitamin K antagonists or contrast media that cannot be adequately premedicated
  12. Patients unsuitable for implantation because of thrombosis of the lower venous system or vena cava filter
  13. The patient has contraindication against a transesophageal echo (TEE) during the procedure
  14. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)
  15. Liver cirrhosis Child C (see appendix)
  16. Female patient of child-bearing potential
  17. Psychiatric or behavioural disease including known alcohol or drug abuser that is likely to impair compliance with protocol
  18. Currently participating in another study of an investigational drug or device that would directly impact the treatment or outcome of the current study
  19. Requirement for Antibiotic Treatment within the last 48 hours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03723239

Layout table for location information
LSMUH Kauno Kliniko
Kaunas, Lithuania
Sponsors and Collaborators
P+F Products + Features GmbH
Layout table for investigator information
Principal Investigator: Alexander Lauten, Prof.Dr.med. Charite University, Berlin, Germany
Principal Investigator: Rimantas Benetis, Prof. Hospital of Lithuanian University of Health Sciences Kauno Klinikos
Layout table for additonal information
Responsible Party: P+F Products + Features GmbH
ClinicalTrials.gov Identifier: NCT03723239    
Other Study ID Numbers: CTP-TRIC-001
First Posted: October 29, 2018    Key Record Dates
Last Update Posted: April 20, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by P+F Products + Features GmbH:
Tricuspid Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Tricuspid Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases